| 2024-07-30 |
复牌提示：
2024-07-30 11:31:03 停牌，复牌日期 2024-07-30 11:36:03
|
| 2024-05-24 |
详情>>
股本变动：
变动后总股本1396.07万股
|
| 2023-12-19 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.28美元,归母净利润-128.56万美元,同比去年增长87.87%
|
| 2023-12-18 |
股东大会：
将于2023-12-29召开股东大会
会议内容 ▼▲
- 1.Election of directors.(1)To elect seven directors to serve on the board of directors of the Company (the “Board”), until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified, assuming Proposal 2 is approved.(2)To elect three Class I nominees to serve on the Board until the 2026 annual meeting, assuming Proposal 2 is not approved.
2.To approve the adoption of an amendment to the Company’s Amended and Restated Bylaws to change the Company’s staggered board (also known as classified board) to a standard board composition.
3.To approve the adoption of an amendment to the Company’s Amended and Restated Certificate of Incorporation to change the Company’s name.
4.To approve, on a non-binding advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement.
5.To approve, on a non-binding advisory basis, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation (“Say When on Pay Vote”) to determine the frequency of future advisory votes on executive compensation.
6.To ratify the appointment of Enrome LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
7.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2023-11-22 |
详情>>
业绩披露：
2023年中报每股收益0.44美元,归母净利润184.37万美元,同比去年增长126.78%
|
| 2023-05-19 |
详情>>
业绩披露：
2023年一季报每股收益-0.23美元,归母净利润-88.42万美元,同比去年增长67.72%
|
| 2023-05-04 |
详情>>
业绩披露：
2022年年报每股收益-8.38美元,归母净利润-2239.33万美元,同比去年增长35.99%
|
| 2023-03-13 |
股东大会：
将于2023-04-13召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Marketplace Rule 5635(a), the issuance of shares of the Company’s common stock (the “Common Stock”) pursuant to the stock purchase agreement dated as of July 5, 2022, as amended on February 27, 2023, between the Company and Mr. Fnu Oudom (“Mr. Oudom”), the Chairman of the board of directors, whereby the Company agreed to issue: (i) 270,000 shares of Common Stock to Mr. Oudom as partial consideration for the Company’s purchase of 100% of the equity interests in Phenix Bio Inc. (“Phenix”) from Mr. Oudom and (ii) 5,000,000 shares of Common Stock to Mr. Oudom in the event Phenix attains a profit of $2,500,000 in 2023;
2.To approve, in accordance with Nasdaq Marketplace Rule 5635(d), the issuance of 2,000,000 shares of Common Stock to Mr. Oudom in consideration for his payment of $3,000,000 pursuant to a stock purchase agreement dated as of February 27, 2023 between the Company and Mr. Oudom;
3.To approve, in accordance with Nasdaq Marketplace Rule 5635(d), the issuance of 1,330,000 shares of Common Stock to Mr. Oudom pursuant to an agreement dated as of February 27, 2023 in consideration for the prepayment of a $2,000,000 convertible promissory note sold by the Company to Mr. Oudom on December 6, 2022;
4.To transact such other business as may properly be brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2022-12-08 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-11-21 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.63美元,归母净利润-1059.71万美元,同比去年增长-99.47%
|
| 2022-08-31 |
详情>>
业绩披露：
2021年年报每股收益-6.51美元,归母净利润-3498.6万美元,同比去年增长-1651.85%
|
| 2022-08-22 |
详情>>
业绩披露：
2022年中报每股收益-0.55美元,归母净利润-688.43万美元,同比去年增长-90.74%
|
| 2022-06-21 |
股东大会：
将于2022-07-13召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees named in the accompanying proxy statement to serve as directors of the Company;
2.To approve the adoption of an amended and restated certificate of incorporation (in the form attached hereto as Annex A) which, among other things: (1) requires stockholder approval to adopt, amend or repeal bylaws of the Company; and (2) eliminates the right of stockholders to take action pursuant to written consent(s);
3.To grant discretionary authority to the board of directors (the “Board”) to amend the Company’s Certificate of Incorporation (as may be amended and restated as described in Proposal 2) to effect a reverse stock split of the common stock of the Company (the “Common Stock”) within the range of 1-2 to 1-10 to be determined by the Board and with the reverse stock split to be effective at such time and date, if at all, as determined by the Board, but not later than the first anniversary of its approval by the stockholders;
4.To approve, in accordance with Nasdaq Marketplace Rules 5635, the sale of 12,500,000 shares of Common Stock of the Company to the Chairman of the Board, Mr. Fnu Oudom, pursuant to a stock purchase agreement dated June 9, 2022;
5.To approve, on a non-binding advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
6.To approve, on a non-binding advisory basis, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation (“Say When on Pay Vote”) to determine the frequency of future advisory votes on executive compensation;
7.To ratify the appointment of Audit Alliance LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022;
8.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-05-20 |
详情>>
业绩披露：
2022年一季报每股收益-0.27美元,归母净利润-273.94万美元,同比去年增长17.82%
|
| 2022-02-14 |
股东大会：
将于2022-03-15召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Marketplace Rule 5635(d), the issuance of shares of the Company’s common stock (the “Common Stock”) upon (i) conversion of the newly issued senior secured convertible notes in the aggregate principal amount of $7,800,000 sold to two institutional investors (the “Institutional Investors”) on November 18, 2021; (ii) conversion of additional senior secured convertible notes in the aggregate principal amount of up to $3,900,000 that may be sold to the Institutional Investors; and (iii) exercise of up to 1,800,000 warrants issued by the Company to the Institutional Investors;
2.To transact such other business as may properly be brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2022-02-03 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2021-11-15 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.23美元,归母净利润-531.27万美元,同比去年增长-1092.2%
|
| 2021-10-07 |
股东大会：
将于2021-11-05召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock (the “Common Stock”) by One Hundred Fifty Million (150,000,000) to Two Hundred Million (200,000,000);
2.To grant discretionary authority to the board of directors of the Company (the “Board”) to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Common Stock within the range of 1-2 to 1-5 (the “Range”) to be determined by the Board and with the reverse stock split to be effective at such time and date, if at all, as determined by the Board, but not later than the first anniversary of its approval by the stockholders.;
3.To transact such other business as may properly be brought before the Special Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-16 |
详情>>
业绩披露：
2021年中报每股收益-0.17美元,归母净利润-360.92万美元,同比去年增长-247.59%
|
| 2021-05-11 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to the Company’s Certificate of Incorporation to change the name of the Company to BIMI International Medical Inc.;
3.To approve, in accordance with Nasdaq Marketplace Rule 5635, the issuance of shares of the Company’s common stock to be issued upon the (i) conversion of $3.3 million of newly issued senior secured convertible notes sold to two institutional investors (the “Institutional Investors”) on February 28, 2021; (ii) exercise of warrants to purchase of up to 760,000 shares of the Company’s common stock issued to the Institutional Investors; and (iii) exercise of warrants to initially purchase 173,745 shares of the Company’s common stock, subject to increase, issued to the placement agent for the private placement of the senior secured convertible notes and warrants to the Institutional Investors;
4.To approve, in accordance with Nasdaq Marketplace Rule 5635, the issuance of 4,600,000 shares of the Company’s common stock to the seller of Chongqing Guanzan Technology Co., Ltd (or her designated assignee(s)), as payment of the balance of the post-closing consideration;
5.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
6.To ratify the appointment of Audit Alliance LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021;
7.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-06-24 |
股东大会：
将于2020-07-24召开股东大会
会议内容 ▼▲
- 1.To elect the five nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve, in accordance with Nasdaq Marketplace Rule 5635(d), the issuance of shares of the Company’s common stock to be issued upon (i) conversion of the newly issued senior secured convertible notes in the aggregate principal amount of $4.45 million sold to two institutional investors (the “Institutional Investors”) on June 2, 2020; (ii) conversion of additional senior secured convertible notes in the aggregate principal amount of up to $2.10 million that may be sold to the Institutional Investors; (iii) exercise of up to 1,300,000 warrants issued to the Institutional Investors; and (iv) exercise of warrants to initially purchase 171,845 shares of the Company’s common stock, subject to increase in the event the Institutional Investors purchase additional senior secured convertible notes, issued to the placement agent for the private placement of the senior secured convertible notes and warrants to the Institutional Investors;
3.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
4.To ratify the appointment of HHC, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020;
5.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2019-10-15 |
股东大会：
将于2019-11-15召开股东大会
会议内容 ▼▲
- 1.To elect seven nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to the Company’s Certificate of Incorporation to change the name of the Company to BOQI International Medical Inc.;
3.To approve, on an advisory basis, the compensation of the Company’s executive officers named in the accompanying proxy statement;
4.To indicate, on an advisory basis, whether future votes to approve executive compensation should occur every one, two, or three years;
5.To ratify the appointment of HHC, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2019;
6.To transact such other business as may properly be brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-04-20 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve for the ensuing year and until their successors are elected.
2.To ratify the selection by the Audit Committee of the Board of Directors of HKCMCPA Company Limited as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To conduct any other business properly brought before the meeting.
|
| 2017-06-30 |
股东大会：
将于2017-07-20召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for the ensuing year and until their successors are elected.
2.To ratify the selection by the Audit Committee of the Board of Directors of HKCMCPA Company Limited as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To conduct any other business properly brought before the meeting.
|
| 2016-08-30 |
股东大会：
将于2016-09-27召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for the ensuing year and until their successors are elected.
2.To ratify the selection by the Audit Committee of the Board of Directors of HKCMCPA Company Limited as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To consider and cast an advisory vote on a non-binding resolution to approve the compensation of the Company’s executive officers disclosed in this Proxy Statement.
4.To conduct any other business properly brought before the meeting.
|
| 2015-11-06 |
股东大会：
将于2015-12-09召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for the ensuing year and until their successors are elected.
2.To ratify the selection by the Audit Committee of the Board of Directors of HKCMCPA Company Limited as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
3.To conduct any other business properly brought before the meeting.
|
| 2014-06-23 |
详情>>
内部人交易：
Psomiadis Themistocles股份减少1800.00股
|